# Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

Study · id `cardio:ct-nct03389100` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03389100](<https://clinicaltrials.gov/study/NCT03389100>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03389100

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 600 participants.

## Technical summary

Registry record NCT03389100. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-07-24 (actual); primary completion 2026-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 2
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT03389100, source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)
- Started: 2018-07-24 (actual) (ClinicalTrials.gov record NCT03389100, source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)
- Primary completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT03389100, source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)
- Completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT03389100, source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03389100, source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03389100-2025-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
- Acronym: NOMEM-Tau
- Condition: Diabetes Mellitus, Type 2
- Condition: Pre-diabetes
- Intervention (Drug): 18F-MK6240 injection
- Lead sponsor: Columbia University
- Lead sponsor class: OTHER
- Collaborator: Hebrew Home at Riverdale
- Collaborator class: OTHER
- Collaborator: National Institute on Aging (NIA)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Columbia University (`cardio:org-columbia-university`)
- Registry lists this organization as a collaborator: National Institute on Aging (`cardio:nia`)

## Provenance

Content hash: 017ea7deb428a789ea36755a4c6ca963a1f127a724eb71dda64775ffaffdbdaf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
